Samsung Bioepis Launches First Biosimilar in Japan

Samsung Bioepis, a subsidiary of Samsung Biologics, has made a significant entry into the Japanese market with the launch of its biosimilar SB17, targeting autoimmune diseases. This move marks a crucial step for the company as it aims to establish a foothold in one of Asia's most important pharmaceutical markets.

The collaboration with Nippo Corporation, a Japanese marketing partner, is key to navigating the complexities of the local healthcare landscape. By leveraging Nippo's expertise, Samsung Bioepis seeks to effectively distribute and promote SB17, which is a biosimilar of Johnson & Johnson's blockbuster drug Stelara.

This launch is not just a commercial milestone for Samsung Bioepis; it represents South Korea's growing prowess in the global biopharmaceutical industry. As the nation continues to invest heavily in research and development, the success of companies like Samsung Bioepis in international markets validates these efforts and positions South Korea as a formidable player in the production of high-quality, affordable biosimilars.

“

Samsung Bioepis has launched its first biosimilar product in Japan, 'SB17' (ustekinumab), for treating autoimmune diseases.